Exclusive Collaboration and License Agreement

 

Theobald Associates is pleased to announce the successful completion of an exclusive collaboration and license agreement between its client Reviral Limited and LianBio. The terms of the collaboration, ReViral will receive an upfront cash payment of $14 million and is eligible to receive development and commercial milestone payments of up to $105 million. Further details can be found at https://reviral.co.uk/reviral-and-lianbio-announce-exclusive-collaboration-and-license-agreement-to-develop-and-commercialize-sisunatovir-in-china/